244 related articles for article (PubMed ID: 34966823)
1. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.
Wen J; Hu H; Chen M; Yang H; Zhao Y; Liu Y
J Immunol Res; 2021; 2021():2324400. PubMed ID: 34966823
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
[TBL] [Abstract][Full Text] [Related]
3. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Zak M; Dengler HS; Rajapaksa NS
Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
[TBL] [Abstract][Full Text] [Related]
4. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Kotyla PJ; Islam MA; Engelmann M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in 2019, synthetic review in 10 points.
Muller R
Eur J Intern Med; 2019 Aug; 66():9-17. PubMed ID: 31178258
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
7. SOCS-JAK-STAT inhibitors and SOCS mimetics as treatment options for autoimmune uveitis, psoriasis, lupus, and autoimmune encephalitis.
Pandey R; Bakay M; Hakonarson H
Front Immunol; 2023; 14():1271102. PubMed ID: 38022642
[TBL] [Abstract][Full Text] [Related]
8. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
10. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
13. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.
Kalantari Y; Sadeghi S; Asadi D; Goodarzi A
Int Immunopharmacol; 2022 Sep; 110():108923. PubMed ID: 35717838
[TBL] [Abstract][Full Text] [Related]
14. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Fragoulis GE; McInnes IB; Siebert S
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
Jamilloux Y; El Jammal T; Vuitton L; Gerfaud-Valentin M; Kerever S; Sève P
Autoimmun Rev; 2019 Nov; 18(11):102390. PubMed ID: 31520803
[TBL] [Abstract][Full Text] [Related]
16. [JAK inhibitors: Perspectives in internal medicine].
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Rev Med Interne; 2019 Dec; 40(12):816-825. PubMed ID: 31699450
[TBL] [Abstract][Full Text] [Related]
17. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
18. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients.
Tóth L; Juhász MF; Szabó L; Abada A; Kiss F; Hegyi P; Farkas N; Nagy G; Helyes Z
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163173
[TBL] [Abstract][Full Text] [Related]
19. JAK Inhibitors: Prospects in Connective Tissue Diseases.
You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
[TBL] [Abstract][Full Text] [Related]
20. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]